{"prompt": "['Trelagliptin-4002', 'Page 39 of 66', 'Version 2.0', 'July 5,10', '9.1.15 Record of study subjects who are withdrawn before randomization', 'A CRF shall be created for all study subjects who have signed the consent form and withdrawn', 'before randomization.', 'The following items are to be described on the CRF.', 'Date of consent obtainment', 'Date of birth', 'Gender', 'Eligibility', 'Reason for discontinuation', 'The primary reason for withdrawal before randomization shall be recorded on the CRF according to', 'the following classification:', 'Not satisfying at least one of the inclusion criteria or meeting any of the exclusion criteria', 'Major protocol deviation', 'Lost to follow-up', 'Voluntary discontinuation (specify the reason)', 'Study termination', 'Pregnancy', 'Others (specify the reason)', 'Study subject ID codes assigned to study subjects withdrawn from the study before randomization', 'shall not be reused.', '9.1.16 Record of randomization', 'Study subjects to be randomized shall meet all of the inclusion criteria and shall not meet any of the', 'exclusion criteria according to Section 8.4. The principal investigator or investigator shall specify', 'the primary reason why the study subject cannot be randomized.', '9.2', 'Implementation time point of the tests and observation', 'The schedule for all tests, observations, and evaluations is shown in Appendix A. The principal', 'investigator or investigator shall perform the tests, observations, and evaluations at the time points', 'shown below.', '9.2.1 Screening period (Week -4)', 'After obtaining informed consent, the physical examination and tests will be performed for the', 'determining eligibility for study enrollment. The eligibility of a patient will be determined based on', 'the inclusion/exclusion criteria presented in the section 7.0. Refer to the section 9.1.16 for the', 'preparation of records on a study subject withdrawn from the study before randomization.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 40 of 66', 'Version 2.0', 'July 5, 2017', 'Tests, observations and evaluations performed at the start of the screening period (Visit 1: Day -29', 'to -1) are shown below.', 'Informed consent', 'Concomitant drugs*', 'Inclusion/ exclusion criteria', 'Comorbidity*', 'Demographic data, medical history', 'Laboratory tests (HbA1c only)', '*', \"Physical examination'\", 'DTR-QOL Questionnaire', 'Height, body weight and BMI', 'The Basic Information on Study', 'Subject (Your Basic Profile) *', '*. To be performed during from Day -29 until Day - -14.', '9.2.2 Treatment period (Week 0)', 'An eligible study subject in consequence of the tests, observations and evaluations before the start of', 'the treatment period will be randomized in accordance with the section 8.4.', 'Tests, observations and evaluations performed at the start of the screening period (Visit 2: Week 0)', 'are shown below.', 'inclusion/exclusion criteria', 'DTR-QOL Questionnaire', 'Physical examination', 'DTSQ', 'Concomitant drugs', 'The Basic Information on Study', 'Subject (Your Basic Profile)', 'Comorbidity', 'Adverse event\"', 'Laboratory tests (blood chemistry and', 'Hospitalization for type 2 diabetes', 'urinalysis)', 'Prescription of the study drug/ or', 'comparative drug', '#: To be performed after the first administration (Day 1).', '9.2.3 Treatment period (Week 4)', 'Tests, observations and evaluations performed during the treatment period (Visit 3: Week 4) are', 'shown below.', 'Physical examination', 'DTR-QOL Questionnaire', 'Concomitant drugs', 'DTSQ', 'Laboratory tests (blood chemistry and', 'The Basic Information on Study', 'urinalysis)', 'Subject (Your Basic Profile)', 'Prescription of the study drug/ or', 'Adverse event', 'comparative drug', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 41 of 66', 'Version 2.0', 'July 5,10', 'Treatment Compliance', 'Hospitalization for type 2 diabetes', '9.2.4 Treatment period (Week 12) or discontinuation', 'Tests, observations and evaluations performed at the end of study treatment (Visit 4: Week 12) are', 'shown below.', 'Physical examination', 'DTR-QOL Questionnaire', 'body weight', 'DTSQ', 'Concomitant drugs', 'The Basic Information on Study', 'Subjects (Your Basic Profile)', 'Laboratory tests (blood chemistry and', 'Adverse event', 'urinalysis)', 'Treatment Compliance', 'Hospitalization for type 2 diabetes', 'Tests, observations and evaluations performed at the discontinuation are shown below.', 'Physical examination', 'DTR-QOL Questionnaire', 'Concomitant drugs', 'DTSQ', 'Laboratory tests (blood chemistry and', 'The Basic Information on Study', 'urinalysis)', 'Subject (Your Basic Profile)', 'Treatment Compliance', 'Adverse event evaluation', 'Hospitalization for type 2 diabetes', 'The reason for the discontinuation', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 42 0f 66', 'Version 2.0', 'July 5, 2017', '10.0', 'ADVERSE EVENTS', '10.1', 'Definitions', '10.1.1 Adverse events', 'An adverse event is defined as any untoward medical occurrence in a patient or a study subject', 'receiving a pharmaceutical product (including the study drug or comparative drug). It does not', 'necessarily have an apparent causal relationship with this pharmaceutical product (including study', 'drug or comparative drug).', 'An adverse event can therefore be any unfavorable and unintended sign (e.g., a clinically significant', 'laboratory abnormality), symptom, or disease temporally associated with the use of a pharmaceutical', 'product (including the study drug or comparative drug), regardless of whether it is considered related', 'to the pharmaceutical product (including the study drug or comparative drug) or not.', '10.1.2 Considerations for adverse events', 'Generally unfavorable findings are described below:', 'Newly diagnosed disease or unexpected aggravation of existing symptom (intermittent event of', 'an existing symptom is not considered an adverse event)', 'Requiring action or medical practice', 'Requiring invasive diagnostic treatment', 'Requiring discontinuation or a change in the dose of the study drug or comparative drug, or a', 'concomitant medication', 'Considered unfavorable by the principal investigator or the investigator', 'Diagnosis name and signs/symptoms:', 'Adverse events shall be recorded by diagnosis name. Accompanying signs (including abnormal', 'laboratory values) and symptoms shall not be recorded as adverse events. If an adverse event could', 'not be expressed by a diagnosis name, the signs or symptoms shall be recorded as the adverse event.', 'Laboratory test values:', 'Abnormal laboratory values shall be recorded as adverse events when the principal investigator or', 'the investigator judges the results are clinically problematic (in other words, when certain action or', 'medical practice is required, or when the principal investigator or the investigator judges the change', 'has exceeded the normal physiological variation range of the study subject). Retest and/or continued', 'CONFIDENTIAL']", "completion": ""}